Table 1.
Baseline characteristics of older medical patients randomised to the anticoagulant fondaparinux or placebo. Values are numbers (percentages) unless stated otherwise
| Characteristic | Fondaparinux group (n=429) | Placebo group (n=420) |
|---|---|---|
| Mean (SD) age (years), range | 75.0 (8.3), 60 to 93 | 74.4 (8.3), 53 to 96* |
| Men | 174 (40.6) | 186 (44.3) |
| Women | 255 (59.4) | 234 (55.7) |
| Mean (SD) weight (kg), range | 70.1 (15.2), 32 to 111 | 70.1 (16.8), 35 to 150 |
| Mean (SD) body mass index | 25.9 (5.5) | 25.8 (5.7) |
| Reason for admission to hospital: | ||
| Congestive heart failure (class III/IV)† | 106 (24.7) | 106 (25.2) |
| Acute respiratory disease | 74 (17.2) | 93 (22.1) |
| Acute infectious or inflammatory disease | 107 (24.9) | 107 (25.5) |
| More than one reason | 142 (33.1) | 114 (27.1) |
| Risk factors for venous thrombembolism: | ||
| Age ≥75 years | 223 (52.0) | 216 (51.4) |
| History of venous thrombembolism‡ | 18 (4.2) | 21 (5.0) |
| Previous or current cancer | 62 (14.5) | 69 (16.4) |
*
One patient recruited out of prespecified range in placebo group (enrolled at age 53) was not included in primary efficacy population.
†
According to New York Heart Association.
‡
Deep vein thrombosis or pulmonary embolism.